VRTX:NGS-Vertex Pharmaceuticals Incorporated (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 422.78

Change

+3.79 (+0.90)%

Market Cap

USD 21.38B

Volume

1.06M

Analyst Target

USD 306.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 108.54B
MRNA Moderna Inc

N/A

USD 63.85B
BNTX BioNTech SE

N/A

USD 22.68B
ARGX argenx NV ADR

N/A

USD 22.05B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 18.78B
GMAB Genmab AS

N/A

USD 18.15B
BGNE BeiGene Ltd

N/A

USD 17.32B
RPRX Royalty Pharma Plc

N/A

USD 15.90B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 14.34B
INCY Incyte Corporation

N/A

USD 12.89B

ETFs Containing VRTX

DCCHAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

USD 0.08B
DCUSAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

USD 0.07B
DCEUAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

USD 0.02B
DCGBAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

USD 2.05M
CURG:LSE VanEck Genomics and Healt.. 8.84 % 0.00 %

N/A

USD 6.79M
2B70:F iShares NASDAQ US Biotech.. 8.65 % 0.00 %

N/A

USD 0.52B
BTEC:SW iShares Nasdaq US Biotech.. 8.65 % 0.00 %

N/A

USD 0.47B
MSGR 8.22 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 8.16 % 0.00 %

N/A

USD 6.79M
UBIO 6.52 % 0.95 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 5.23 % 0.57 %

N/A

USD 0.26B
LIFE-U:CA Evolve Global Healthcare .. 5.00 % 0.00 %

N/A

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.78 % 0.00 %

N/A

USD 3.46M
ZWHC:CA BMO Covered Call Health C.. 4.59 % 0.00 %

N/A

CAD 0.01B
XNNS:LSE Xtrackers MSCI Innovation.. 4.54 % 0.00 %

N/A

USD 7.78M
XNNV:LSE Xtrackers MSCI Innovation.. 4.54 % 0.00 %

N/A

USD 7.78M
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.35 % 0.00 %

N/A

USD 3.46M
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.30 % 0.00 %

N/A

USD 0.15B
XNNV:XETRA Xtrackers MSCI Innovation.. 4.21 % 0.00 %

N/A

USD 7.78M
FTXH First Trust Nasdaq Pharma.. 3.99 % 0.60 %

N/A

USD 0.02B
FBT:LSE First Trust Global Funds .. 3.67 % 0.00 %

N/A

USD 5.46M
FBTU:LSE First Trust Global Funds .. 3.67 % 0.00 %

N/A

USD 5.46M
XDGI:XETRA Xtrackers MSCI Global SDG.. 3.63 % 0.00 %

N/A

USD 0.01B
HEAL:CA 3.39 % 0.00 %

N/A

N/A
CACG ClearBridge All Cap Growt.. 3.31 % 0.53 %

N/A

USD 0.13B
CDNA:CA CI Bio-Revolution ETF 3.09 % 0.00 %

N/A

CAD 5.81M
UPWD 2.43 % 0.00 %

N/A

N/A
QQXT First Trust NASDAQ-100 Ex.. 1.85 % 0.60 %

N/A

USD 0.14B
XLVE:CA Mulvihill U.S. Health Car.. 1.69 % 0.00 %

N/A

CAD 7.13M
ESMV iShares ESG MSCI USA Min .. 1.57 % 0.00 %

N/A

USD 0.01B
MVEA:SW iShares Edge MSCI USA Min.. 1.56 % 0.00 %

N/A

USD 0.31B
MVEW:LSE iShares Edge MSCI World M.. 1.48 % 0.00 %

N/A

USD 0.54B
FLXU:LSE Franklin LibertyQ U.S. Eq.. 1.13 % 0.00 %

N/A

USD 0.18B
FRUE:LSE Franklin LibertyQ U.S. Eq.. 1.13 % 0.00 %

N/A

USD 0.18B
THNZ:XETRA L&G Global Thematic ESG E.. 0.90 % 0.00 %

N/A

USD 4.34M
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD 0.44B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.09B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD 3.03M
DEF 0.00 % 0.59 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 7.10B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

N/A

USD 0.13B
SPGP Invesco S&P 500 GARP ETF 0.00 % 0.36 %

N/A

USD 4.91B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

N/A

USD 0.06B
ZPW-U:CA BMO US Put Write ETF 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.47B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.47B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.04B
VLQ:CA 0.00 % 0.40 %

N/A

N/A
ZBIO 0.00 % 0.95 %

N/A

N/A
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 3.32M
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
SMRT:PA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.03B
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
SM8T:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.04B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
ZINN:CA 0.00 % 0.00 %

N/A

N/A
MVEA:XETRA iShares Edge MSCI USA Min.. 0.00 % 0.00 %

N/A

USD 0.32B
NVQ 0.00 % 0.00 %

N/A

N/A
SMRU:PA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 3.28M
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.91% 60% D- 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.91% 60% D- 62% D
Trailing 12 Months  
Capital Gain 21.69% 76% C+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.69% 76% C+ 71% C-
Trailing 5 Years  
Capital Gain 150.39% 89% A- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 150.39% 89% A- 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 19.85% 73% C 79% B-
Dividend Return 19.85% 73% C 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.01% 89% A- 65% D
Risk Adjusted Return 70.85% 98% N/A 90% A-
Market Capitalization 21.38B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 28.66 19% 32%
Price/Book Ratio 5.83 24% 19%
Price / Cash Flow Ratio 29.04 2% 9%
Price/Free Cash Flow Ratio 20.00 2% 12%
Management Effectiveness  
Return on Equity 22.99% 98% 92%
Return on Invested Capital 18.99% 90% 88%
Return on Assets 13.17% 100% 97%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.